Portuguese Global Medicines Access Index 2021—An Indicator to Measure Access to Hospital Medicines

IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES
Sofia Oliveira-Martins PhD , Miguel Costa Lopes MPharm , Alexandra Cardoso dos Santos MA, MBA , Ana Margarida Advinha PhD
{"title":"Portuguese Global Medicines Access Index 2021—An Indicator to Measure Access to Hospital Medicines","authors":"Sofia Oliveira-Martins PhD ,&nbsp;Miguel Costa Lopes MPharm ,&nbsp;Alexandra Cardoso dos Santos MA, MBA ,&nbsp;Ana Margarida Advinha PhD","doi":"10.1016/j.vhri.2023.11.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Access to innovative and effective medication is a citizen’s right. The main objectives of this study were to build an indicator to measure access to medicines within hospitals, the Global Medicines Access Index, and to identify the main existing barriers.</p></div><div><h3>Methods</h3><p>Cross-sectional study carried out in Portuguese National Health Service hospitals. A consensus methodology (expert panel of 7 members) was used to define which dimensions should be included in the index and the weighting that each should take. The panel identified 6 dimensions: access to innovative medicines, proximity distribution, shortages, access to medicines before financing decision, value-based healthcare, and access to medication depending on cost/funding. Data were collected through an electronic questionnaire (September 2021).</p></div><div><h3>Results</h3><p>The response rate was 61.2%. Most hospitals used medicines with and without marketing authorization before the funding decision. Monitoring and generating evidence of new therapies results is still insufficient. The identified barriers were the administrative burden as the major barrier in purchasing medicines, with a relevant impact on shortages of medicines. Most respondents (87%) had a proximity distribution program, mainly implemented in the pandemic context, and the price/funding model was only identified by 10% as a barrier to access. The 2021 Global Medicines Access Index was 66%. Shortages and value-based use of medicines were the dimensions that had more influence in lowering the index value.</p></div><div><h3>Conclusions</h3><p>The new formula used to obtain a unique and multidimensional index for access to hospital medicines seems to be more sensitive and objective and will be used to monitor access.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"41 ","pages":"Pages 80-85"},"PeriodicalIF":1.4000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212109923001401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Access to innovative and effective medication is a citizen’s right. The main objectives of this study were to build an indicator to measure access to medicines within hospitals, the Global Medicines Access Index, and to identify the main existing barriers.

Methods

Cross-sectional study carried out in Portuguese National Health Service hospitals. A consensus methodology (expert panel of 7 members) was used to define which dimensions should be included in the index and the weighting that each should take. The panel identified 6 dimensions: access to innovative medicines, proximity distribution, shortages, access to medicines before financing decision, value-based healthcare, and access to medication depending on cost/funding. Data were collected through an electronic questionnaire (September 2021).

Results

The response rate was 61.2%. Most hospitals used medicines with and without marketing authorization before the funding decision. Monitoring and generating evidence of new therapies results is still insufficient. The identified barriers were the administrative burden as the major barrier in purchasing medicines, with a relevant impact on shortages of medicines. Most respondents (87%) had a proximity distribution program, mainly implemented in the pandemic context, and the price/funding model was only identified by 10% as a barrier to access. The 2021 Global Medicines Access Index was 66%. Shortages and value-based use of medicines were the dimensions that had more influence in lowering the index value.

Conclusions

The new formula used to obtain a unique and multidimensional index for access to hospital medicines seems to be more sensitive and objective and will be used to monitor access.

葡萄牙《2021 年全球药品可及性指数--衡量医院药品可及性的指标》。
目标:获得创新和有效的药物是公民的权利。本研究的主要目的是建立一个衡量医院内药物可及性的指标--全球药物可及性指数,并确定目前存在的主要障碍:方法:在葡萄牙国民健康服务医院开展横断面研究。采用协商一致的方法(由 7 名成员组成的专家小组)确定指数应包括哪些方面,以及每个方面所占的权重。专家小组确定了 6 个维度:获得创新药物、就近分配、药物短缺、在做出资助决定前获得药物、基于价值的医疗保健以及根据成本/资助情况获得药物。数据通过电子问卷收集(2021 年 9 月):答复率为 61.2%。大多数医院在做出资助决定前使用了获得或未获得上市许可的药物。对新疗法结果的监测和证据生成仍然不足。已确定的障碍是行政负担是采购药品的主要障碍,并对药品短缺产生相关影响。大多数受访者(87%)都有近距离分发计划,主要是在大流行病背景下实施的,只有 10%的受访者认为价格/资助模式是获取药品的障碍。2021 年全球药品获取指数为 66%。药品短缺和以价值为基础的药品使用是对降低指数值影响较大的因素:新公式用于获得独特的、多维度的医院药品可及性指数,似乎更加敏感和客观,将用于监测药品可及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Value in health regional issues
Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
2.60
自引率
5.00%
发文量
127
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信